Intensity Therapeutics

INTSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$10.186 M

$3.12 -12.61%

Close of 6 Nov 2026

As of 6 Nov 2026, Intensity Therapeutics (INTS) has a market capitalization of $10.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$11.6M

Loss-making

Shares outstanding

3,301,175

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#148TScan TherapeuticsTCRX$11.5M
#149Passage BIOPASG$11.1M
#150Intensity TherapeuticsINTS$10.2M
#151In8bioINAB$8.30M
#152Senti BiosciencesSNTI$6.33M

What if Intensity Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$8,648,674

Per share 2,772,100× higher

Bitcoin $1.53T

$467,964.69

Per share 149,993× higher

Apple $5.02T

$1,536,284

Per share 492,415× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for Intensity Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.